Compare TOWN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | BEAM |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | 1939 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | N/A | 2019 |
| Metric | TOWN | BEAM |
|---|---|---|
| Price | $36.63 | $25.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $50.75 |
| AVG Volume (30 Days) | 724.9K | ★ 2.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $35.63 | N/A |
| Revenue Next Year | $5.18 | $33.77 |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $31.91 | $15.60 |
| 52 Week High | $37.86 | $38.26 |
| Indicator | TOWN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 30.23 |
| Support Level | $35.12 | $24.80 |
| Resistance Level | $37.44 | $33.32 |
| Average True Range (ATR) | 0.70 | 1.99 |
| MACD | -0.03 | -0.94 |
| Stochastic Oscillator | 72.88 | 1.83 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.